Jinxin Reproduction (1951.HK) 2023 Report Review: The 23-year performance is in line with expectations and is expected to usher in a recovery in 24
Jinxin Reproduction (01951.HK) Hong Kong Stock Company Information Update Report: Fast recovery in 2023, the new Shenzhen campus is expected to be put into operation in 2025
Open Source Securities: Maintaining Jinxin Reproduction's (01951) “Buy” rating, Shenzhen's new hospital is expected to be put into operation
Jinxin Reproduction (1951.HK): Performance is in line with expectations, domestic and foreign operations have resumed steadily
Jinxin Reproduction (1951.HK) Annual Report Review: Steady Revenue Growth Continues to Focus on Profit Margin Recovery
Jinxin Reproduction (1951.HK): ARS business is recovering, overseas/new business can be expected
Jinxin Reproduction (1951.HK): The number of cycles is growing steadily, and the company's profitability continues to improve
Nomura Adjusts Jinxin Fertility Group's Price Target to HK$6.24 From HK$8.20, Keeps at Buy
Jinxin Reproduction (01951.HK): Regional adjustments have achieved remarkable results and the business situation is gradually recovering
Jinxin Reproduction (1951.HK): The company's business is recovering steadily, and the assisted reproduction industry is expected to accelerate growth
Jinxin Reproduction (01951.HK): Effective improvement of service capabilities and continuous development of international business
Jinxin Reproduction (1951.HK): Steady business growth, self-building+acquisitions to further expand business network
Bank Rating丨Goldman Sachs: Give Jin Xin a reproductive target price of HK$4.8 rating “neutral”
Nomura Adjusts Jinxin's Price Target to HK$8.20 From HK$8.90, Keeps at Buy
Changes in Hong Kong stocks | Jin Xin Breeding (01951) rose more than 5%, institutions say the company's market share is expected to rise steadily to maintain the “recommended” rating
Jin Xin Reproduction (1951.HK): Lightweight and optimistic about business recovery at home and abroad
Nomura Adjusts Jinxin Fertility’s Price Target to HK$8.90 From HK$8.71, Keeps at Buy
Nomura: Maintaining Jinxin Reproduction (01951) “Buy” Rating Target Price Raised to HK$8.9
CICC: Maintaining Jin Xin Reproduction's (01951) “Outperform the Industry” rating target price of HK$8.8
Jin Xin Reproduction (01951.HK): Assisted reproduction is included in medical insurance, and we can expect a steady recovery in post-epidemic business
No Data